Rapamycin & mTOR
Early evidenceSafety and tolerability of delayed-release rapamycin in cats with subclinical hypertrophic cardiomyopathy (RAPACAT)
Fries R.C. et al. · Journal of Veterinary Internal Medicine, 2023
- Species
- Cats
- Design
- Randomized controlled trial
- Sample
- Client-owned cats with subclinical HCM
What it found
A randomized, double-blind, placebo-controlled trial of once-weekly delayed-release rapamycin in cats. The drug was well tolerated at the doses studied; the trial was designed around safety and tolerability rather than a lifespan endpoint.
Why it matters
Cats are chronically understudied and are not small dogs — they metabolize drugs differently. This is one of the very few controlled rapamycin trials in cats, and it is why feline dosing can be discussed at all rather than guessed at.
How much weight this carries
Promising mechanism with mostly preclinical or small-sample human data. We flag the uncertainty.
This link runs a PubMed search on the paper’s exact title rather than a hard-coded DOI. It always resolves to the real record, and it cannot rot.
More on rapamycin & mtor
- Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Nature, 2009
- Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice
eLife, 2016
- A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs
GeroScience, 2017
- TRIAD — Test of Rapamycin In Aging Dogs
Dog Aging Project, 2024
The content on this site is for informational purposes only and is not veterinary advice. These statements have not been evaluated by a food or drug regulatory authority and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a licensed veterinarian about your pet's health.